See more : Scout24 SE (G24.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Scholar Rock Holding Corporation (SRRK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scholar Rock Holding Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Barco NV (BCNAY) Income Statement Analysis – Financial Results
- Concord Acquisition Corp III (CNDB-UN) Income Statement Analysis – Financial Results
- Wacoal Holdings Corp. (WACLY) Income Statement Analysis – Financial Results
- TCPL Packaging Limited (TCPLPACK.NS) Income Statement Analysis – Financial Results
- The Bank of Nova Scotia (0UKI.L) Income Statement Analysis – Financial Results
Scholar Rock Holding Corporation (SRRK)
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 33.19M | 18.82M | 15.40M | 20.49M | 0.00 | 0.00 | 379.00K |
| Cost of Revenue | 2.84M | 9.89M | 9.02M | 74.06M | 54.22M | 807.00K | 669.00K | 12.48M |
| Gross Profit | -2.84M | 23.31M | 9.79M | -58.66M | -33.73M | -807.00K | -669.00K | -12.10M |
| Gross Profit Ratio | 0.00% | 70.22% | 52.04% | -380.83% | -164.58% | 0.00% | 0.00% | -3,192.08% |
| Research & Development | 121.90M | 124.44M | 108.47M | 74.06M | 54.22M | 36.31M | 19.94M | 12.48M |
| General & Administrative | 49.40M | 43.12M | 40.27M | 28.22M | 20.82M | 14.38M | 5.09M | 4.11M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.40M | 43.12M | 40.27M | 28.22M | 20.82M | 14.38M | 5.09M | 4.11M |
| Other Expenses | 0.00 | -132.00K | -1.88M | 395.00K | 3.54M | -56.00K | -10.00K | 22.00K |
| Operating Expenses | 171.30M | 167.56M | 148.74M | 102.28M | 75.03M | 50.69M | 25.03M | 16.59M |
| Cost & Expenses | 171.30M | 167.56M | 148.74M | 102.28M | 75.03M | 50.69M | 25.03M | 16.59M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42M | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.84M | 9.89M | 9.02M | 3.87M | 2.30M | 807.00K | 669.00K | 575.00K |
| EBITDA | -168.45M | -131.38M | -127.29M | -85.39M | -53.24M | -49.89M | -24.36M | -15.64M |
| EBITDA Ratio | 0.00% | -404.81% | -676.52% | -564.03% | -266.16% | 0.00% | 0.00% | -4,125.33% |
| Operating Income | -171.30M | -134.37M | -129.92M | -86.88M | -54.54M | -50.69M | -25.03M | -16.21M |
| Operating Income Ratio | 0.00% | -404.81% | -690.48% | -564.03% | -266.16% | 0.00% | 0.00% | -4,277.04% |
| Total Other Income/Expenses | 5.51M | -132.00K | -1.88M | 395.00K | 3.54M | 1.37M | 34.00K | 3.00K |
| Income Before Tax | -165.79M | -134.50M | -131.80M | -86.48M | -51.00M | -49.33M | -25.00M | -16.21M |
| Income Before Tax Ratio | 0.00% | -405.21% | -700.46% | -561.47% | -248.88% | 0.00% | 0.00% | -4,276.25% |
| Income Tax Expense | 0.00 | -2.85M | 2.39M | -1.49M | -1.30M | 1.37M | -44.00K | 19.00K |
| Net Income | -165.79M | -131.65M | -131.80M | -84.99M | -49.70M | -49.33M | -25.00M | -16.21M |
| Net Income Ratio | 0.00% | -396.61% | -700.46% | -551.79% | -242.52% | 0.00% | 0.00% | -4,276.25% |
| EPS | -1.99 | -2.21 | -3.59 | -2.77 | -1.80 | -3.15 | -1.40 | -0.91 |
| EPS Diluted | -1.99 | -2.21 | -3.59 | -2.77 | -1.80 | -3.15 | -1.40 | -0.91 |
| Weighted Avg Shares Out | 83.35M | 59.61M | 36.71M | 30.73M | 27.54M | 15.66M | 17.91M | 17.91M |
| Weighted Avg Shares Out (Dil) | 83.35M | 59.61M | 36.71M | 30.73M | 27.54M | 15.66M | 17.91M | 17.91M |
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Transcript
Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering
Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross?
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Here's Why Everybody's Talking About Scholar Rock Right Now
Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants
Source: https://incomestatements.info
Category: Stock Reports